A Proposal to Make Biomedical Research into Alzheimer's Disease More Democratic Following an International Survey with Researchers
- PMID: 34632301
- PMCID: PMC8461732
- DOI: 10.3233/ADR-210030
A Proposal to Make Biomedical Research into Alzheimer's Disease More Democratic Following an International Survey with Researchers
Abstract
Background: Therapeutic research into Alzheimer's disease (AD) has been dominated by the amyloid cascade hypothesis (ACH) since the 1990s. However, targeting amyloid in AD patients has not yet resulted in highly significant disease-modifying effects. Furthermore, other promising theories of AD etiology exist.
Objective: We sought to directly investigate whether the ACH still dominates the opinions of researchers working on AD and explore the implications of this question for future directions of research.
Methods: During 2019, we undertook an international survey promoted with the help of the Alzheimer's Association with questions on theories and treatments of AD. Further efforts to promote a similar study in 2021 did not recruit a significant number of participants.
Results: 173 researchers took part in the 2019 survey, 22% of which held "pro-ACH" opinions, tended to have more publications, were more likely to be male, and over 60. Thus, pro-ACH may now be a minority opinion in the field but is nevertheless the hypothesis on which the most clinical trials are based, suggestive of a representation bias. Popular vote of all 173 participants suggested that lifestyle treatments and anti-tau drugs were a source of more therapeutic optimism than anti-amyloid treatments.
Conclusion: We propose a more democratic research structure which increases the likelihood that promising theories are published and funded fairly, promotes a broader scientific view of AD, and reduces the larger community's dependence on a fragile economic model.
Keywords: Alzheimer’s disease; amyloid-β; dementia prevention; diversity in science; gender; lifestyle factors; lifestyle interventions; pharmaceutical industry; tau protein; women in science.
© 2021 – The authors. Published by IOS Press.
Conflict of interest statement
Timothy Daly, Marion Houot, Anouk Barberousse, and Amélie Petit declare no conflicts of interest. Stéphane Epelbaum has received consulting fees from Biogen, Roche, Eisai and GE Healthcare.
Figures

Similar articles
-
Amyloid-β in Alzheimer's Disease: A Study of Citation Practices of the Amyloid Cascade Hypothesis Between 1992 and 2019.J Alzheimers Dis. 2020;74(4):1309-1317. doi: 10.3233/JAD-191321. J Alzheimers Dis. 2020. PMID: 32250306
-
Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.Alzheimers Res Ther. 2021 Mar 25;13(1):64. doi: 10.1186/s13195-021-00799-3. Alzheimers Res Ther. 2021. PMID: 33766132 Free PMC article. Clinical Trial.
-
A critical analysis of the 'amyloid cascade hypothesis'.Folia Neuropathol. 2014;52(3):211-25. Folia Neuropathol. 2014. PMID: 25310732 Review.
-
Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent βAPP mRNA Amplification. An Engine that Drives Alzheimer's Disease.Ann Integr Mol Med. 2019;1(1):61-74. Epub 2019 Nov 20. Ann Integr Mol Med. 2019. PMID: 31858090 Free PMC article.
-
The amyloid cascade hypothesis: are we poised for success or failure?J Neurochem. 2016 Oct;139 Suppl 2:237-252. doi: 10.1111/jnc.13632. Epub 2016 Jun 3. J Neurochem. 2016. PMID: 27255958 Review.
Cited by
-
From Association to Intervention: The Alzheimer's Disease-Associated Processes and Targets (ADAPT) Ontology.J Alzheimers Dis. 2023;94(s1):S87-S96. doi: 10.3233/JAD-221004. J Alzheimers Dis. 2023. PMID: 36683508 Free PMC article. Review.
-
Are trailblazing trials for reducing cognitive decline putting the cart before the horse?Alzheimers Dement (N Y). 2022 Jun 13;8(1):e12298. doi: 10.1002/trc2.12298. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35733646 Free PMC article. No abstract available.
-
Against Over-reliance on PRISMA Guidelines for Meta-analytical Studies.Rambam Maimonides Med J. 2024 Jan 19;15(1):e0004. doi: 10.5041/RMMJ.10518. Rambam Maimonides Med J. 2024. PMID: 38261347 Free PMC article.
-
Synthetic amyloid beta does not induce a robust transcriptional response in innate immune cell culture systems.J Neuroinflammation. 2022 Apr 23;19(1):99. doi: 10.1186/s12974-022-02459-1. J Neuroinflammation. 2022. PMID: 35459147 Free PMC article.
-
Alzheimer's research after full approval of lecanemab: impetus and variety.Dement Neuropsychol. 2024 Jan 5;17:e20230064. doi: 10.1590/1980-5764-DN-2023-0064. eCollection 2023. Dement Neuropsychol. 2024. PMID: 38189032 Free PMC article. No abstract available.
References
-
- Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, Zetterberg H (2014) Pathways to Alzheimer’s disease. J Intern Med 275, 296–303. - PubMed
-
- Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter C, Clerici M, Cosby SL, Del Tredici K, Field H, Fulop T, Grassi C, Griffin WS, Haas J, Hudson AP, Kamer AR, Kell DB, Licastro F, Letenneur L, Lövheim H, Mancuso R, Miklossy J, Otth C, Palamara AT, Perry G, Preston C, Pretorius E, Strandberg T, Tabet N, Taylor-Robinson SD, Whittum-Hudson JA (2016) Microbes and Alzheimer’s disease. J Alzheimers Dis 51, 979–984. - PMC - PubMed
-
- Zollman K (2010) The epistemic benefit of transient diversity. Erkenntnis 72, 17–35.
LinkOut - more resources
Full Text Sources